Literature DB >> 18976801

Pitfalls in immunohistochemical validation of tumor marker expression--exemplified in invasive cancer of the uterine cervix.

Dan Hellberg1, Tibor Tot, Ulf Stendahl.   

Abstract

OBJECTIVES: To study if immunohistochemical expression of tumor markers as prognostic predictors is influenced by clinical stage, adjustments for expression of other tumor markers and histological type in cervical cancer.
METHODS: The study included 129 women with squamous cell cancer and 29 women with adenocarcinomas. Expression of 9 tumor markers relevant for cervical cancer and selected to represent different mechanisms in carcinogenesis was analysed. These were Ki-67, c-myc, LRIG1, p-53, p-27, CD44, VEGF, Cox-2 and CD4+.
RESULTS: In late-stage cancer a higher number of tumor-infiltrating CD4 positive cells were associated with a favourable prognosis while a higher Ki-67 index with a poor prognosis. In early-stage cancer a high LRIG1 expression was associated with a favourable prognosis. Significantly different expressions were found at early-stage versus at late-stage squamous cell cancer for VEGF, p27 and LRIG1 which were all more strongly expressed in early stages. Adjustments for all selected tumor markers and clinical stage converted VEGF and LRIG1 expression from non-significant to significant prognostic predictors while the association between p53 expression and good prognosis was strengthened. Adjustments for Cox-2 and c-myc had the strongest impact on VEGF as a prognosis predictor and LRIG1 was most influenced by adjustment for p53. All correlations became non-significant when women with adenocarcinoma and other invasive tumor types were included.
CONCLUSIONS: Failure to analyse clinical stages separately, failure to adjust for expression of relevant concurrent tumor markers and inclusion of different histological subtypes into the same study group may lead to false conclusions regarding the significance of prognostic tumor markers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18976801     DOI: 10.1016/j.ygyno.2008.09.013

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  Promoter region methylation and loss of protein expression of PTEN and significance in cervical cancer.

Authors:  Qiufeng Qi; Yang Ling; Ming Zhu; Linyan Zhou; Meizhen Wan; Yanqing Bao; Yongping Liu
Journal:  Biomed Rep       Date:  2014-06-16

2.  Exon-array profiling unlocks clinically and biologically relevant gene signatures from formalin-fixed paraffin-embedded tumour samples.

Authors:  J S Hall; H S Leong; L S C Armenoult; G E Newton; H R Valentine; J J Irlam; C Möller-Levet; K A Sikand; S D Pepper; C J Miller; C M L West
Journal:  Br J Cancer       Date:  2011-03-15       Impact factor: 7.640

3.  Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis.

Authors:  Tamara R Litwin; Sarah R Irvin; Rebecca L Chornock; Vikrant V Sahasrabuddhe; Margaret Stanley; Nicolas Wentzensen
Journal:  Br J Cancer       Date:  2020-12-01       Impact factor: 7.640

Review 4.  LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.

Authors:  Y Wang; E J Poulin; R J Coffey
Journal:  Br J Cancer       Date:  2013-04-04       Impact factor: 7.640

5.  LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.

Authors:  Qungen Xiao; Minhai Dong; Fangling Cheng; Feng Mao; Weifeng Zong; Kang Wu; Heping Wang; Ruifan Xie; Baofeng Wang; Ting Lei; Dongsheng Guo
Journal:  Int J Oncol       Date:  2018-07-16       Impact factor: 5.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.